BioNxt Solutions Inc.
VANCOUVER, BC / ACCESSWIRE / July 17, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a statement of work ("SOW") with a German-based international contract research, development, and manufacturing organization (the "CRDMO"). The SOW is focused on the Company's flagship Cladribine oral dissolvable film ("ODF") development program.
The SOW sets out a number of important deliverables, including but not limited to technology transfer and implementation, evaluation batch production (GMP material under GMP conditions), stability testing, cGMP manufacturing of clinical study samples, and preparation of the PK study Investigational Medical Product Dossier for EU submission.
BioNxt is developing a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The CRDMO has a head office in Munich, Germany, with an international network of pharmaceutical service providers with facilities in five countries and over 500 employees. They offer GCP/GLP/GMP/ISO/IEC-certified services and GMP certified manufacturing of clinical trial supplies (Phase I-III) with a specialization in solids, semi-solids, liquids, oral films, and transdermal patches as well as integrated lab analytical services during development & GMP manufacturing, including API characterization, method development, optimization, validation, permeation studies, stabilities studies, etc.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Nittetsu Mining Provides Final $1.5 Million Earn-in Payment for Camino's Los Chapitos Copper Project in Peru3.12.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / December 3, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the receipt of the sixth, and final, CAD$1.5 million payment from its exploration partner Nittetsu Mining CO., Ltd. ("Nittetsu"), marking the successful completion of Nittetsu's earn-in expenditure requirements under the earn-in agreement dated June 13, 2023 ("Earn-In Agreement") (see news release dated June 14, 2023). Following the conclusion of the current drilling program at the Los Chapitos Copper Project ("Los Chapitos" or the "Project") in Peru, the Project will be formally converted into a joint venture, with Camino retaining a 65% participating interest, operatorship of the Project, and 50% of the life-of-mine production off-take. Los Chapitos is the second joint venture project with Nittetsu, as Camino is currently advancing the Puquios copper mine development with Nittetsu in Chile. At Los Chapitos, exploration drilling has
GoodData Ushers in Era of Governed and Trustworthy AI Analytics3.12.2025 11:00:00 CET | Press release
New Intelligence Layer allows enterprises to ground AI in governed data, ensuring precision, explainability, and confidence in every decision. SAN FRANCISCO, CA / ACCESS Newswire / December 3, 2025 / GoodData, leader in AI analytics and data intelligence, today announced the launch of its Intelligence Layer, a suite of governed, context-aware AI capabilities that bridge the gap between raw data and trustworthy, action-ready intelligence. Built for organizations operating across complex data environments, whether on-premises or across cloud services, the Intelligence Layer ensures that AI is grounded in a company's own rules, logic, and semantic definitions. Roman Stanek, CEO of GoodData, says: "Most companies don't need more dashboards; they need clarity. They need to know their data is right, easy to understand, and ready to use. That's exactly what the Intelligence Layer is built for." The Intelligence Layer embeds governance and business context directly into the analytical process,
Caldwell Expands Global Financial Services and Real Estate Capabilities with Addition of Ben Sturnham as Partner3.12.2025 11:00:00 CET | Press release
LONDON, UK AND TORONTO, ON / ACCESS Newswire / December 3, 2025 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Ben Sturnham as a Partner in the firm's Financial Services and Real Estate practices. Based in London, Sturnham advises clients on board and C-suite recruitment across the full breadth of the real estate, financial services, and real estate finance sectors in the UK, Europe, and the Middle East. With more than two decades of global experience in executive search, leadership assessment, and organizational development, Sturnham is known for helping investors, lenders, and operators build high-performing leadership teams. "Ben is a deeply respected search professional whose insight, credibility, and sector knowledge make him an exceptional advisor to clients across the financial services and real estate capital ecosystem," said Glenn Buggy and Paul Heller, global managing partners of Caldwell's Financial Services Practice. "His ap
New GTDC Report Highlights Effective Methods for Building Optimal Channel Strategies2.12.2025 15:00:00 CET | Press release
TAMPA, FL / ACCESS Newswire / December 2, 2025 / The Global Technology Distribution Council (GTDC) has released a groundbreaking new industry study titled "Building the Optimal Distribution Strategy." This comprehensive guide provides insights and valuable best practices for evaluating market and channel coverage needs and determining which types of distributors provide the best fit for technology suppliers. Former global channel chief and partner route to market specialist Donna Grothjan led the development of this member-inspired GTDC project, adding her personal knowledge and experience creating and managing distribution strategies, as well as gathering and sharing insight from respected industry peers and subject matter experts. Distribution remains the most cost-effective route-to-market for technology suppliers. That value is rising rapidly in the cloud era as emerging and legacy vendors look to scale sales, support and other operations around these virtual offerings without requ
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases2.12.2025 06:00:00 CET | Press release
Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly volunteers, supporting its advancement into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / December 2, 2025 / GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, CA (United States) today. SUL-238 was originally discovered by Sulfateq and has since been further developed through a collaborative effort of Sulfateq and GEN as a novel therapeutic in neurodegenerative diseases. This Phase 1 randomized, d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom